AI Article Synopsis
- Researchers evaluated the effectiveness and side effects of combining chemoradiotherapy (CCRT) with durvalumab for treating locally advanced non-small cell lung cancer (LA-NSCLC) with N3 lymph node metastasis, comparing it to CCRT alone.
- The study analyzed data from 29 patients who underwent treatment between 2008 and 2022, focusing on local control, progression-free survival, and overall survival, with a median follow-up of 22 months.
- Results showed a significantly higher one-year local control rate for the durvalumab group (89%) compared to the CCRT-alone group (47%), but there was no difference in progression-free or overall survival; however, both groups experienced notable pneumonitis
Article Abstract
Background/aim: Efficacy and toxicity of concurrent chemoradiotherapy (CCRT) and durvalumab for locally advanced non-small cell lung cancer (LA-NSCLC) with N3 lymph node metastasis remain unclear. We aimed to evaluate the clinical outcomes of patients who received CCRT and durvalumab (durvalumab cohort) and compare their outcomes with those of patients who received CCRT alone (CCRT-alone cohort).
Patients And Methods: The data of patients who had received treatment between November 2008 and February 2022 and were followed up for at least 3 months were retrospectively analyzed. Local control, progression-free survival, and overall survival were evaluated using Kaplan-Meier analysis and compared using the log-rank test. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events version 5.0.
Results: The data of 29 patients were analyzed (median follow-up period: 22 months). Among them, 17 received CCRT alone and 12 received CCRT and durvalumab. There were 14 patients with stage IIIB and 15 with stage IIIC LA-NSCLC. The durvalumab cohort (89%) had a significantly higher 1-year local control rate than the CCRT-alone cohort (47%; p=0.035). No significant difference was observed in either progression-free or overall survival between the two cohorts. Grade ≥2 pneumonitis was observed in 6 (50%) and 7 (41%) patients in the durvalumab and CCRT-alone cohorts, respectively.
Conclusion: CCRT with durvalumab may be effective against LA-NSCLC with N3 lymph node metastasis. The incidence of grade 2 pneumonitis was slightly higher in the durvalumab cohort than in the CCRT-alone cohort, suggesting the need for careful patient monitoring after treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.16205 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18.
JTO Clin Res Rep
December 2024
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Article Synopsis
- - The study investigates the effectiveness of durvalumab maintenance therapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC) after receiving concurrent chemoradiotherapy (CCRT), comparing those with specific genetic mutations to those without.
- - A total of 339 patients were analyzed, revealing similar progression-free survival (PFS) rates of 21.4 months for wild-type and 21.0 months for mutant groups, while significant differences in PFS were noted based on programmed death-ligand 1 (PD-L1) expression levels.
- - The findings suggest that while genetic mutations did not significantly alter outcomes, PD-L1 expression levels had a notable impact on PFS, highlighting the importance
Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process.
Curr Oncol
October 2024
Division of Medical Oncology, Dalhousie University, Queen Elizabeth II Health Sciences Centre, Halifax, NS B3H 1V8, Canada.
The addition of durvalumab consolidation to concurrent chemoradiation therapy (cCRT) has fundamentally changed the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC). Nevertheless, concerns related to esophagitis and pneumonitis potentially impact the broad application of all regimen components. A Canadian expert working group (EWG) was convened to provide guidance to healthcare professionals (HCPs) managing these adverse events (AEs) and to help optimize the patient experience.
View Article and Find Full Text PDFReal-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer.
PLoS One
November 2024
The US Oncology Network, Blacksburg, Virginia, United States of America.
Article Synopsis
- - In 2018, durvalumab, an immune checkpoint inhibitor, was introduced as a treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy; however, many still experienced cancer progression.
- - This study analyzed data from 426 patients who underwent concurrent chemoradiotherapy (cCRT) between 2017 and 2019, focusing on their survival and progression outcomes through a follow-up ending in 2022.
- - Results showed that patients who received cCRT plus durvalumab had a median overall survival of 50.2 months compared to 11.6 months for those who only had cCRT, indicating a significant benefit from adding durvalumab
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study.
Cancer Treat Res Commun
December 2024
Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-gun, 411-8777, Shizuoka, Japan.
Objectives: The current standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. Although the trial revealed the survival benefit of adding an immune checkpoint inhibitor (ICI) to the population, the optimal treatment strategy and efficacy of subsequent treatment after relapse remain unclear.
Materials And Methods: We retrospectively collected data from patients with unresectable LA-NSCLC who completed platinum-based CCRT as first-line treatment.
Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy.
Target Oncol
November 2024
BC Cancer-Victoria, 2410 Lee Avenue V8R 6V5, Victoria, BC, Canada.
Background: Concurrent chemoradiotherapy (cCRT) followed by 1 year of the immune checkpoint inhibitor (ICI) durvalumab is standard of care for patients with unresectable stage III nonsmall cell lung cancer (NSCLC).
Objectives: The purpose of this study was to evaluate survival outcomes of (1) cCRT followed by durvalumab in patients older versus younger than 75 years of age and (2) post-progression treatment with ICI alone versus chemotherapy alone versus combined ICI and chemotherapy.
Patients And Methods: Patients with unresectable stage III NSCLC treated between January 2018 and July 2023 with cCRT followed by durvalumab were identified retrospectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!